Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.14365/994
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTepedelen, Burcu Erbaykent-
dc.contributor.authorKorkmaz, Mehmet-
dc.contributor.authorTatlisumak, Ertugrul-
dc.contributor.authorUluer, Elgin Tukoz-
dc.contributor.authorOlmez, Ercument-
dc.contributor.authorDegerli, Ismail-
dc.contributor.authorSoya, Elif-
dc.date.accessioned2023-06-16T12:48:17Z-
dc.date.available2023-06-16T12:48:17Z-
dc.date.issued2017-
dc.identifier.issn0163-4984-
dc.identifier.issn1559-0720-
dc.identifier.urihttps://doi.org/10.1007/s12011-016-0918-6-
dc.identifier.urihttps://hdl.handle.net/20.500.14365/994-
dc.description.abstractEvidences about the preventive and therapeutic effects of boron compounds on cancer have been increasing in the last years. Although calcium fructoborate (CaFB) is used as a nutritional supplement, data about its preventive and therapeutic effects on neoplastic transformations are limited. In the present study, the various concentrations of CaFB were applied to the MDA-MB-231 metastatic breast cancer cell line. First, we examined the cytotoxic effect and IC50 value of CaFB by MTT assay. For the evaluation of the DNA damage, apoptosis and metastatic potential, expression levels of ATM, pATM, PARP, p53, p-p53, caspase-3, caspase-9, and VEGF were investigated by using immunoblotting and immunohistochemical methods. Cell viability was significantly reduced at 50 mu M CaFB treatment. pATM, p-p53, and caspase-9 levels increased significantly in all groups; furthermore, there was approximately 12.5-, 2.4-, and 10.7-fold increase, respectively, for 100 mu M CaFB treatment. ATM and p53 levels did not change with CaFB treatment, but PARP levels significantly 2.5-fold decreased. While VEGF immunoreactivity decreased in all groups, significant increase in caspase-3 immunoreactivity was observed only in the group treated with 50 mu M CaFB ( p < 0,001). Our results imply that CaFB may have therapeutic potential as well as preventive benefits in cancer.en_US
dc.description.sponsorshipTurkish Scientific and Technological Research Council [TUBITAK 113S700]en_US
dc.description.sponsorshipThis research was supported with grants (TUBITAK 113S700) from the Turkish Scientific and Technological Research Council.en_US
dc.language.isoenen_US
dc.publisherSpringernatureen_US
dc.relation.ispartofBıologıcal Trace Element Researchen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectMDA-MB-231en_US
dc.subjectBoronen_US
dc.subjectCalcium fructoborateen_US
dc.subjectDNA damageen_US
dc.subjectApoptosisen_US
dc.subjectVEGFen_US
dc.subjectInhibits Human Prostateen_US
dc.subjectBreast-Canceren_US
dc.subjectDietary Boronen_US
dc.subjectBoric-Aciden_US
dc.subjectPhenylboronic Aciden_US
dc.subjectGrowthen_US
dc.subjectSupplementationen_US
dc.subjectMechanismsen_US
dc.subjectApoptosisen_US
dc.subjectMigrationen_US
dc.titleA Study on the Anticarcinogenic Effects of Calcium Fructoborateen_US
dc.typeArticleen_US
dc.identifier.doi10.1007/s12011-016-0918-6-
dc.identifier.pmid28028787en_US
dc.identifier.scopus2-s2.0-85007420804en_US
dc.departmentİzmir Ekonomi Üniversitesien_US
dc.authoridSoya, Elif/0000-0002-7956-1315-
dc.authoridInan, Sevinc/0000-0003-1971-9720-
dc.authorwosidKorkmaz, Mehmet/N-8168-2015-
dc.authorwosidTepedelen, Burcu Erbaykent/AAH-6436-2021-
dc.authorwosidSoya, Elif/AGE-9174-2022-
dc.authorwosiduluer, elgin/AAN-2767-2021-
dc.authorscopusid47860936500-
dc.authorscopusid36677416200-
dc.authorscopusid6506838303-
dc.authorscopusid54584495800-
dc.authorscopusid6603585456-
dc.authorscopusid57192690813-
dc.authorscopusid57189218920-
dc.identifier.volume178en_US
dc.identifier.issue2en_US
dc.identifier.startpage210en_US
dc.identifier.endpage217en_US
dc.identifier.wosWOS:000405475800006en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.scopusqualityQ1-
dc.identifier.wosqualityQ2-
item.grantfulltextreserved-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.openairetypeArticle-
item.fulltextWith Fulltext-
item.languageiso639-1en-
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection
Files in This Item:
File SizeFormat 
4356.pdf
  Restricted Access
963.64 kBAdobe PDFView/Open    Request a copy
Show simple item record



CORE Recommender

SCOPUSTM   
Citations

9
checked on Oct 2, 2024

WEB OF SCIENCETM
Citations

7
checked on Oct 2, 2024

Page view(s)

52
checked on Sep 30, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.